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cer-specific quality of life dimension scores are signifi-
cantly related to EuroQol-5D scores.
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OBJECTIVE: In an era of cost-conscientiousness and
budgetary restraints, the cost-effectiveness of lipid modu-
lator agents must be considered. The study objective was
to evaluate the cost-effectiveness ratio of lipid modulator
agents, based on the agent’s effects on total cholesterol/
HDL-cholesterol ratio (TC/HDL-c) and on the cost of ac-
quisition.
METHODS: The choice of TC/HDL-c for the efficacy
criterion was dictated by the overwhelming evidence that
it is the most predictive parameter in assessing CHD risk
when compared to other lipid/lipoprotein levels or ratios.
Also, the evidence supporting the crucial role played by
HDL is demonstrated in several studies, among which are
the Framingham Study, LRC-CPPT, MRFIT, and PRO-
CAM. The cost of acquisition of each medication was ob-
tained from the Quebec Provincial Formulary (Liste de
Medicament—July 1996). The meta-analysis of each dose
of each medication’s effects on TC/HDL was based on a
search generating 456 publications, from which 124 met
the appropriate criteria. 
RESULTS: From these publications, on average, the pop-
ulation is 50.5 years old, with 62.5% males; the baseline
TC/HDL is 7.3. The various doses of each medication
were ranked into three categories of efficacy based on the
percent decrease of the TC/HDL ratio: less than 20%,
20–30%, and greater than 30%.
CONCLUSION: In the most effective category, the medi-
cations which showed the best efficacy to cost ratio were
fluvastatin 60 mg (20% decrease per $ per day) and mi-
cronized fenofibrate 200 mg (19% decrease per $ per
day), and then simvastatin 20 mg (15% decrease per $
per day).
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In a previous analysis, based on the West of Scotland
Coronary Prevention Study (WOSCOPS), pravastatin
was demonstrated to lower the risk of cardiovascular dis-
ease (CVD) in hypercholesterolemic men, at an economic
efficiency that is not prohibitive overall from the perspec-
tive of the National Health Service in the UK. For these
results to provide guidance to those who set policy in
other jurisdictions, they must account for differences
among healthcare systems.
OBJECTIVE: The applicability of these findings to the
Belgian setting was investigated by integrating the
WOSCOPS results and Belgian epidemiological, resource
use, and cost data.
METHODS: The Belgian Interuniversity Research on
Nutrition and Health data were used to evaluate the
baseline risk factor distribution and to partially validate
the CVD exponential regression model derived from
WOSCOPS. The rates at which subjects move for the first
time from health to CVD were calculated, assuming the
relative efficacy for pravastatin observed in WOSCOPS.
The number of such transitions avoided was valued in
terms of cost savings to the Belgian healthcare system and
life-years gained. Resource use and costs were primarily
derived from diagnosis-related expenditure in a subset of
Belgian hospitals. Belgian life table data were obtained
and substituted for the Scottish data to account for differ-
ences in life expectancy.
RESULTS: The cost-effectiveness ratio remains well be-
low USD 25,000 (BEF 37  USD 1) per life-year gained,
the bound typically considered as “moderate to strong
evidence for adoption and appropriate utilization.”
CONCLUSION: Although the precise estimate depends
on the specifics of the country, the variation does not
have an impact on the treatment decision the initial study
supports.
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To determine the efficacy of cardiac inpatient rehabilita-
tion therapy (RT), 2442 consecutive patients (78% male,
age 60 (10 years), and 22% female, age 65 (10
years) in 18 rehabilitation centers were examined in the
period from January to June 1997. The primary indica-
tions for RT were myocardial infarction (56%), PTCA
(6%), and CABG (38%). RT was initiated 34 days (me-
dian) after the acute event. During hospitalization (26 
5 days), patients received standard health training and
medical therapy. Diagnostic tests and standardized sur-
veys were prospectively documented. The prevalence of
conventionally defined cardiovascular risk factors at the
start and end of the rehabilitation therapy is shown in the
table below.
